Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The …
JJ Petersen, CK Jørgensen, P Faltermeier, F Siddiqui… - BMJ open, 2023 - bmjopen.bmj.com
Objectives To assess the effects of interventions authorised by the European Medicines
Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 …
Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 …
Development and Validation of In-vitro Release Study of Molnupiravir Capsules by RP-HPLC
Introduction: The coronavirus disease-2019 (COVID-19) outbreak all over the world has led
researchers to strive to develop treatment and preventive measures to control its …
researchers to strive to develop treatment and preventive measures to control its …